Branched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis

Target: BCAT1/BCAT2 Composite Score: 0.400 Price: $0.40 Citation Quality: Pending metabolomics Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

⚠ Missing Evidence⚠ Thin Description⚠ Low Validation Senate Quality Gates →

Quality Report Card click to collapse

Composite: 0.400

Top 87% of 1402 hypotheses

T4 Speculative

Novel AI-generated, no external validation

Needs 1+ supporting citation to reach Provisional

C+ Mech. Plausibility 15% 0.50 Top 76%

C Evidence Strength 15% 0.40 Top 80%

C Novelty 12% 0.45 Top 97%

C Feasibility 12% 0.45 Top 71%

C Impact 12% 0.45 Top 89%

C+ Druggability 10% 0.50 Top 61%

D Safety Profile 8% 0.30 Top 92%

F Competition 6% 0.20 Top 98%

C Data Availability 5% 0.40 Top 87%

D Reproducibility 5% 0.35 Top 92%

Evidence

4 supporting | 4 opposing

Citation quality: 0%

Debates

1 session C+

Avg quality: 0.50

Convergence

0.00 F 6 related hypothesis share this target

From Analysis:

Metabolomic signatures of neurodegeneration: metabolic reprogramming in aging brains

What are the key metabolic alterations detectable in brain tissue, CSF, and blood during neurodegeneration, and can metabolomic biomarkers predict disease progression before clinical symptoms appear? How does the brain's metabolic landscape shift from glycolysis toward alternative energy substrates in AD, and what does this reveal about bioenergetic failure as a driver versus consequence of pathology?

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Metabolic Catastrophe

Score: 0.520 | Target: PARP1, SIRT1/3, NAD+

Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation

Score: 0.450 | Target: SLC16A1 (MCT1)

Apolipoprotein E4-Mediated Metabolic Dysfunction Correction via Liver X Receptor Agonism

Score: 0.380 | Target: NR1H2 (LXRβ), APOE

Mitochondrial Pyruvate Carrier Inhibition to Force Metabolic Reprogramming Toward Ketone Utilization

Score: 0.350 | Target: MPC1/MPC2

Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacological Activation of Monocarboxylate Transporters

Score: 0.320 | Target: SLC16A3 (MCT4)

Blood-Brain Barrier Metabolite Transporter Enhancement for Diagnostic and Therapeutic Dual Benefit

Score: 0.220 | Target: SLCO2A1 (OATP2A1)

→ View full analysis & all 7 hypotheses

Description

Branched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

8 citations 6 with PMID Validation: 0% 4 supporting / 4 opposing

✓ For (4)

No supporting evidence

No opposing evidence

(4) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 6CLIN 2GENE 0EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Metabolomic studies report elevated plasma BCAAs i…	Supporting	CLIN	-	-	-	-	PMID:30239921	-
BCAT1 expression is reduced in AD hippocampus, cor…	Supporting	MECH	-	-	-	-	PMID:25486095	-
BCAA supplementation paradoxically improves cognit…	Supporting	MECH	-	-	-	-	PMID:28214415	-
Mouse model studies demonstrate that BCAT inhibiti…	Supporting	MECH	-	-	-	-	PMID:25199829	-
BCAA supplementation shows mixed cognitive effects…	Opposing	MECH	-	-	-	-	PMID:30189549	-
BCAT has dual functions - global inhibition could …	Opposing	MECH	-	-	-	-	-	-
Brain BCAT activity is highly regulated by leucine…	Opposing	MECH	-	-	-	-	PMID:28873279	-
Industry programs (Janssen) for BCAT inhibitors dr…	Opposing	CLIN	-	-	-	-	-	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 4

Metabolomic studies report elevated plasma BCAAs in AD patients, with decreased utilization in brain tissue

PMID:30239921

BCAT1 expression is reduced in AD hippocampus, correlating with decreased glutamate recycling capacity

PMID:25486095

BCAA supplementation paradoxically improves cognitive function in some aging studies

PMID:28214415

Mouse model studies demonstrate that BCAT inhibition reduces glutamate-mediated excitotoxicity in stroke model…▼

Mouse model studies demonstrate that BCAT inhibition reduces glutamate-mediated excitotoxicity in stroke models

PMID:25199829

✗ Opposing Evidence 4

BCAA supplementation shows mixed cognitive effects in meta-analyses - larger trials fail to replicate cognitiv…▼

BCAA supplementation shows mixed cognitive effects in meta-analyses - larger trials fail to replicate cognitive benefits

PMID:30189549

BCAT has dual functions - global inhibition could disrupt glutamate homeostasis unpredictably, causing excitot…▼

BCAT has dual functions - global inhibition could disrupt glutamate homeostasis unpredictably, causing excitotoxicity or synaptic failure

Brain BCAT activity is highly regulated by leucine which affects mTOR signaling - distinguishing BCAT-specific…▼

Brain BCAT activity is highly regulated by leucine which affects mTOR signaling - distinguishing BCAT-specific effects challenging

PMID:28873279

Industry programs (Janssen) for BCAT inhibitors dropped due to unclear efficacy

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-18 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Therapeutic Hypotheses: Metabolomic Signatures of Neurodegeneration

Hypothesis 1: Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation

Title: MCT1 transporter upregulation as a therapeutic strategy to compensate for cerebral glucose hypometabolism in Alzheimer's disease

Description: Neuronal MCT1 (SLC16A1) expression declines in AD brain, limiting utilization of circulating ketone bodies as alternative fuel. Therapeutic upregulation of neuronal MCT1 using novel brain-penetrant small molecules could restore ketonemia-derived ATP production in neurons suff

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Metabolomic Hypotheses for Neurodegeneration

I'll provide a rigorous scientific critique of each hypothesis, identifying weaknesses, counter-evidence, alternative explanations, and falsification experiments.

Hypothesis 1: MCT1 Upregulation for Ketone Body Utilization

Specific Weaknesses

1. Causal Direction Ambiguity: The cited reduction in MCT1/MCT4 protein (PMID:25716827) may represent a compensatory downregulation to reduce lactate export from metabolically compromised cells, rather than a primary pathogenic mechanism. Without demonstrating that

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Drug Discovery Assessment: Metabolomic Hypotheses for Neurodegeneration

Executive Summary

All seven hypotheses face significant translational barriers. The metabolomics field provides genuine mechanistic insight but suffers from over-reliance on postmortem data, species translation gaps, and absence of validated CNS pharmacodynamic biomarkers. No hypothesis has a clear path to IND-enabling studies within standard timelines.

Below is the systematic evaluation:

Hypothesis 1: MCT1 (SLC16A1) Upregulation

Is the Target Druggable?

Marginally. MCT1 is a 12-transmembra

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

Low

0.0000

Events (7d)

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (6)

Paper:25199829

No extracted figures yet

Paper:25486095

No extracted figures yet

Paper:28214415

No extracted figures yet

Paper:28873279

No extracted figures yet

Paper:30189549

No extracted figures yet

Paper:30239921

No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Metabolomic signatures of neurodegeneration: metabolic reprogramming in aging brains — Analysis Notebook

Analysis notebook for the knowledge gap: Metabolomic signatures of neurodegeneration: metabolic reprogramming in aging brains

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.50

31.7th percentile (747 hypotheses)

Tokens Used

KG Edges Generated

Citations Produced

Cost Ratios

Cost per KG Edge

0.00 tokens

Lower is better (baseline: 2000)

Cost per Citation

0.00 tokens

Lower is better (baseline: 1000)

Cost per Score Point

0.00 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.050

10% weight of efficiency score

Adjusted Composite

0.450

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

KG Entities (6)

BCAT1/BCAT2 MPC1/MPC2 NR1H2 (LXRβ), APOE PARP1, SIRT1/3, NAD+SLC16A1 (MCT1)metabolomics

Related Hypotheses

NAD+ Precursor Supplementation to Reverse Poly(ADP-ribose) Polymerase-Driven Metabolic Catastrophe

Score: 0.520 | metabolomics

Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation

Score: 0.450 | metabolomics

Apolipoprotein E4-Mediated Metabolic Dysfunction Correction via Liver X Receptor Agonism

Score: 0.380 | metabolomics

Mitochondrial Pyruvate Carrier Inhibition to Force Metabolic Reprogramming Toward Ketone Utilization

Score: 0.350 | metabolomics

Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacological Activation of Monocarboxylate Transporters

Score: 0.320 | metabolomics

Estimated Development

Estimated Cost

Timeline

0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (5 edges)

implicates in (5)

PARP1, SIRT1/3, NAD+→metabolomicsSLC16A1 (MCT1)→metabolomicsBCAT1/BCAT2→metabolomicsNR1H2 (LXRβ), APOE→metabolomicsMPC1/MPC2→metabolomics

Mechanism Pathway for BCAT1/BCAT2

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    PARP1__SIRT1_3__NAD_["PARP1, SIRT1/3, NAD+"] -->|implicates in| metabolomics["metabolomics"]
    SLC16A1__MCT1_["SLC16A1 (MCT1)"] -->|implicates in| metabolomics_1["metabolomics"]
    BCAT1_BCAT2["BCAT1/BCAT2"] -->|implicates in| metabolomics_2["metabolomics"]
    NR1H2__LXR____APOE["NR1H2 (LXRβ), APOE"] -->|implicates in| metabolomics_3["metabolomics"]
    MPC1_MPC2["MPC1/MPC2"] -->|implicates in| metabolomics_4["metabolomics"]
    style PARP1__SIRT1_3__NAD_ fill:#4fc3f7,stroke:#333,color:#000
    style metabolomics fill:#ef5350,stroke:#333,color:#000
    style SLC16A1__MCT1_ fill:#4fc3f7,stroke:#333,color:#000
    style metabolomics_1 fill:#ef5350,stroke:#333,color:#000
    style BCAT1_BCAT2 fill:#ce93d8,stroke:#333,color:#000
    style metabolomics_2 fill:#ef5350,stroke:#333,color:#000
    style NR1H2__LXR____APOE fill:#4fc3f7,stroke:#333,color:#000
    style metabolomics_3 fill:#ef5350,stroke:#333,color:#000
    style MPC1_MPC2 fill:#ce93d8,stroke:#333,color:#000
    style metabolomics_4 fill:#ef5350,stroke:#333,color:#000

3D Protein Structure

🧬 BCAT1 — Search for structure Click to search RCSB PDB

🔍 Searching RCSB PDB for BCAT1 structures...

Querying Protein Data Bank API

Source Analysis

Metabolomic signatures of neurodegeneration: metabolic reprogramming in aging brains

metabolomics | 2026-04-16 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Branched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis

Hypotheses from Same Analysis (6)

Description

Dimension Scores

✓ Supporting Evidence 4

✗ Opposing Evidence 4

Therapeutic Hypotheses: Metabolomic Signatures of Neurodegeneration

Hypothesis 1: Restoration of Neuronal Ketone Body Utilization via MCT1 Upregulation

Critical Evaluation of Metabolomic Hypotheses for Neurodegeneration

Hypothesis 1: MCT1 Upregulation for Ketone Body Utilization

Specific Weaknesses

Drug Discovery Assessment: Metabolomic Hypotheses for Neurodegeneration

Executive Summary

Hypothesis 1: MCT1 (SLC16A1) Upregulation

Is the Target Druggable?

Price History

Clinical Trials (0)

📚 Cited Papers (6)

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Hypotheses from Same Analysis (6)

🧬 Same Target Gene / Disease (6)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

KG Entities (6)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions

Knowledge Subgraph (5 edges)

implicates in (5)

Mechanism Pathway for BCAT1/BCAT2

3D Protein Structure

Source Analysis

Metabolomic signatures of neurodegeneration: metabolic reprogramming in aging brains

Community Feedback